MedTrace Logo

Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial

NCT04820751 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-04-02

No results posted yet for this study

Summary

This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.

Conditions

  • Viral Pneumonia
  • Serotonin Syndrome
  • Platelet Dysfunction

Interventions

DRUG

Cyproheptadine Hydrochloride 4 MG

Cyproheptadine associated to standard care

Sponsors & Collaborators

  • Covid-19 Early Treatment Fund

    collaborator OTHER

  • Ciusss de L'Est de l'Île de Montréal

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-10
Primary Completion
2021-11-01
Completion
2022-01-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04820751 on ClinicalTrials.gov